• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Robert W. Baird initiated coverage on Contineum Therapeutics with a new price target

    10/22/24 6:13:41 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTNM alert in real time by email
    Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00
    Get the next $CTNM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTNM

    DatePrice TargetRatingAnalyst
    6/20/2025Outperform
    William Blair
    10/22/2024$32.00Outperform
    Robert W. Baird
    More analyst ratings

    $CTNM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Contineum Therapeutics to Present at September Investor Conferences

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the following investor conferences in September. Cantor Global Healthcare Conference 2025 – fireside chat on Thursday, September 4, 2025, at 9:10 a.m. ET. Morgan Stanley 23rd Annual Global Healthcare Conference – fireside chat on Monday, September 8, 2025, at 8:30 a.m. ET. Baird 2025 Global Healthcare Conference – fireside chat on Tuesday, September 9, 2025, at 2:00 p.m. ET. An audio webcast of t

    8/28/25 4:05:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

    - Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025 - Initiation of a global Phase 2 proof-of-concept clinical trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF) in the fourth quarter of 2025 - Cash runway projected to fund operations through 2027 Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its second-quarter 2025 financial results and updated its key clinical develop

    8/5/25 4:05:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progressive multiple sclerosis (PrMS) cohorts of this trial. The screening and enrollment of idiopathic pulmonary fibrosis (IPF) patients to participate in this trial is ongoing. "In early June, consistent with our protocol, we enr

    6/25/25 8:15:00 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.

    SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)

    8/14/25 4:26:41 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Contineum Therapeutics Inc.

    10-Q - Contineum Therapeutics, Inc. (0001855175) (Filer)

    8/5/25 4:13:32 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Contineum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)

    8/5/25 4:08:50 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Boyce Sarah

    4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

    6/26/25 5:50:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Schimmelpennink Evert B.

    4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

    6/26/25 5:47:53 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Brady Todd R.

    4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

    6/26/25 5:46:34 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Contineum Therapeutics

    William Blair initiated coverage of Contineum Therapeutics with a rating of Outperform

    6/20/25 7:53:37 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Robert W. Baird initiated coverage on Contineum Therapeutics with a new price target

    Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00

    10/22/24 6:13:41 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Leadership Updates

    Live Leadership Updates

    View All

    Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

    4/28/25 4:05:00 PM ET
    $CTNM
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

    3/17/25 4:05:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

    1/6/25 8:00:00 AM ET
    $CTNM
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Contineum Therapeutics Inc.

    SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)

    11/14/24 4:38:16 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care